iRay Technology Company Limited: history, ownership, mission, how it works & makes money

Founded on March 7, 2011 in Shanghai, iRay Group has evolved from a specialized flat panel X‑ray detector maker into a publicly traded innovator (ticker 688301) whose 2019 operating revenue reached 546.11 million RMB with net income of 95.32 million RMB, and whose recent scale is reflected in 2024 revenue of 1.83 billion RMB and net income of 465.18 million RMB; listed on the STAR Market on September 18, 2020, the company-renamed iRay Group effective February 2025-now reports a market capitalization of 21.22 billion RMB and a stock price of 100.50 RMB as of December 12, 2025, operates production in Shanghai, Taicang and Seoul, exports to about 80 countries, employs over 2,000 people, invests heavily in innovation (R&D was 12.24% of revenue in 2020), and maintains a diversified shareholder base including Tianjin Sequoia and Beijing Sequoia holding 14,330,985 shares (6.78%) as of November 11, 2025, positioning its product portfolio-and revenue model across medical, dental, oncology, veterinary, security and industrial markets-for continued technological and geographic expansion.

iRay Technology Company Limited (688301.SS): Intro

• Founded: March 7, 2011 (Shanghai, China)
• Primary products: Flat panel X‑ray detectors, digital radiography systems, modular imaging solutions
• Listing: Sci‑Tech Innovation Board (STAR Market), Shanghai Stock Exchange - ticker 688301 (listed 2020‑09‑18)
• Name change: December 2024 announced Chinese name change to "Yirui Electronic Technology Group Co., Ltd." and English change to "iRay Group" effective Feb 2025

History & Milestones

• 2011 - Company established focusing on flat panel detector R&D and manufacture.
• 2019 - Operating revenue 546.11 million RMB; net income 95.32 million RMB (YoY +20.31% revenue, +58.85% net income).
• 2020 - Successful IPO on STAR Market (688301.SS) to strengthen capital base and R&D investment.
• 2024 - Revenue 1.83 billion RMB (-1.74% vs prior year); net income 465.18 million RMB (-23.43% YoY).
• 2025 - Market position reflected by stock price 100.50 RMB and market cap 21.22 billion RMB (as of 2025‑12‑12).

Ownership & Corporate Structure

• Publicly traded entity on SSE STAR Market (688301.SS) - free float and institutional investors hold majority of tradable shares post‑IPO.
• Founders and management retain strategic stakes to align long‑term R&D and commercialization objectives.
• Group structure post‑2025 uses iRay Group as the English brand for consolidated operations and subsidiaries handling manufacturing, R&D, and overseas distribution.

Mission, Vision & Core Values

iRay's mission centers on advancing digital X‑ray imaging to improve diagnostic access and efficiency across clinical and industrial settings. For the official, up‑to‑date presentation of mission, vision and values see: Mission Statement, Vision, & Core Values (2026) of iRay Technology Company Limited.

How the Technology Works

iRay designs and manufactures flat panel X‑ray detectors (FPDs) that convert X‑ray photons into electronic signals for digital imaging. Core components and workflow:

• Detector layer: Direct or indirect conversion materials (e.g., amorphous selenium or scintillator + photodiode arrays).
• Readout electronics: High‑speed ASICs and FPGA‑based processing for low noise, high dynamic range capture.
• Image processing: Proprietary algorithms for noise reduction, dose optimization, and enhanced diagnostic contrast.
• System integration: Modular detector modules integrated into DR rooms, mobile units, dental chairs, CT/CBCT add‑ons, security scanners.

Revenue Streams & Business Model - How iRay Makes Money

Primary revenue sources:

• Product sales - flat panel detectors, complete digital radiography systems, and ancillary imaging hardware.
• System integration and customization - revenue from OEM partnerships and tailored installations for hospitals, dental clinics, and industrial users.
• After‑sales services - maintenance contracts, spare parts, software upgrades, and extended warranties.
• Licensing & channel partnerships - licensing imaging IP and selling through global distributors.

Key Financial Snapshot

Products & Market Applications

• Medical: DR systems for general radiography, pediatric, emergency, orthopedics, oncology imaging modules.
• Dental: High‑resolution sensors and intraoral imaging solutions.
• Veterinary: Portable and clinic‑grade imaging systems.
• Security & Industrial: Baggage scanners, nondestructive testing detectors and specialized industrial inspection systems.

R&D, Manufacturing & Competitive Positioning

• R&D focus: Detector materials, ASIC readout, dose reduction algorithms, AI‑assisted image enhancement.
• Manufacturing: In‑house production of detector panels and system assembly to control quality and margins.
• Competitive advantages: Integrated detector + system capabilities, vertical manufacturing, and a diversified application footprint across clinical and industrial segments.

iRay Technology Company Limited (688301.SS): History

• Ownership Structure (key points as of late 2025): Tianjin Sequoia and Beijing Sequoia jointly held 14,330,985 shares (6.78% stake) as of November 11, 2025, after selling 1,000,000 shares via block trade.
• Public Market: Listed on the Shanghai Stock Exchange under 688301 with a market capitalization of 21.22 billion RMB on December 12, 2025.
• Shareholder Base: Broad mix of institutional and retail investors, with notable participation from venture capital firms and strategic industry partners influencing governance and strategic direction.
• Financial Trend: 2024 revenue totaled 1.83 billion RMB, a decline of 1.74% from 2023's 1.86 billion RMB, indicating a modest contraction in sales that year.

• How ownership affects strategy: significant institutional and VC shareholders provide capital, strategic partnerships, and influence on R&D prioritization, M&A appetite, and capital allocation.
• Recent ownership change: the 1,000,000-share block trade reduced Sequoia group holdings and slightly altered the balance among large shareholders, with potential impacts on voting power and liquidity.

iRay Technology Company Limited (688301.SS): Ownership Structure

• Mission: Advance X‑ray imaging through development of detectors, collimators, generators, ionization chambers and high‑energy linear accelerators to become a leading global supplier of digital X‑ray core components.
• Values: Quality, customer satisfaction, continuous improvement, employee development, health & safety, and environmental stewardship.
• ESG focus: Energy‑saving projects, process optimization for reduced GHG emissions, and corporate governance that supports sustainable growth.

• Revenue: RMB 1.05 billion (FY2023, reported/rounded)
• Net profit: RMB 150 million (FY2023, reported/rounded)
• R&D investment: ~12% of revenue (~RMB 126 million)
• International sales: ~35% of revenues, expanding in Europe, North America and Asia markets

• Founder/management control (~38%) preserves long‑term R&D direction and product roadmap continuity.
• Strategic investors (~22%) provide industry partnerships, component sourcing and market access for systems (medical, oncology, security).
• Institutional and public shareholders supply capital for capacity expansion, green projects and entry into high‑energy accelerator components.

• Component sales: detectors, X‑ray tubes, generators and ionization chambers to OEMs and system integrators (primary revenue stream).
• Subsystems and modules: higher‑margin integrated detector modules and collimator assemblies for medical/dental markets.
• After‑sales and service: maintenance, software upgrades and detector calibration contracts.
• New product expansion: planned entry into high‑energy linear accelerators and oncology subsystems to capture higher ASP (average selling price) segments.

iRay Technology Company Limited (688301.SS): Mission and Values

iRay Technology Company Limited (688301.SS) is a Shanghai‑headquartered developer and manufacturer of digital X‑ray imaging systems and components. The company operates a centralized management model from its Shanghai headquarters to coordinate R&D, production, quality control and global sales.

How it works operationally:

• Centralized management in Shanghai overseeing strategy, product development and global commercial operations.
• Manufacturing footprint includes production facilities in Shanghai and Taicang, China, and a facility in Seoul, Korea, enabling regional supply chain flexibility and shorter lead times for key markets.
• Integrated product development lifecycle from detector materials and X‑ray sources to high‑voltage generators and imaging software.
• Global distribution network exporting to approximately 80 countries, including the United States and numerous European markets.

Core product portfolio:

• Wireless and tethered digital radiography detectors
• Mammography detectors and systems
• Dynamic / real‑time flat panel detectors and linear detector arrays
• X‑ray and micro‑focus X‑ray sources
• High‑voltage generators and power electronics
• Radiation detecting materials (e.g., scintillators) and detector substrates
• Imaging and workflow software for clinical and industrial applications

Key operational and financial metrics (representative figures):

Revenue model - how iRay makes money:

• Product sales: primary revenue from detectors, X‑ray sources, generators and complete imaging systems sold to hospitals, clinics, industrial inspection firms and OEM partners.
• OEM and module sales: supplying detector modules, scintillators and electronics to other medical device manufacturers and industrial equipment producers.
• After‑sales services & consumables: maintenance contracts, calibration, software upgrades and consumables (detector care, spare parts).
• Software and solutions: imaging/diagnostic software licensing and system integration services for hospital information ecosystems.

R&D and competitive positioning:

• Heavy emphasis on R&D to improve detector sensitivity, image quality and portability - demonstrated by a 12.24% R&D spend relative to operating revenue in 2020.
• Focus areas include wireless detector miniaturization, high‑efficiency scintillators, low‑dose imaging and real‑time dynamic detectors for angiography and interventional radiology.
• Vertical integration across detector materials, X‑ray sources and electronics helps control costs and protect intellectual property.

Global commercial footprint and growth drivers:

• Export network across ~80 countries drives diversified revenue streams and reduces single‑market risk.
• Adoption in both medical and non‑destructive testing (industrial) markets expands addressable market.
• Strategic production locations (China and Korea) support both domestic scale and export responsiveness to key markets such as Europe and the US.

Further reading:

iRay Technology Company Limited (688301.SS): How It Works

• Core product families: wireless/tethered flat-panel detectors (DR), mammography detectors, dynamic/real-time detectors (for fluoroscopy and C-arm use), and linear detector arrays for industrial/ security inspection.
• End markets served: medical (hospitals and clinics), dental, oncology, veterinary, security (airport/port screening) and industrial inspection.
• Sales channels: direct sales to large hospital groups, national distributors for mid-sized buyers, international partners for export markets, and service/support contracts for maintenance and upgrades.

• Hardware sales: primary revenue from X-ray detector units, integrated radiography systems and turn-key digital rooms.
• Software and licensing: PACS integration, image enhancement algorithms, AI-based diagnostics modules and cloud services sold as licenses or subscriptions.
• Service contracts: extended warranties, maintenance, training, and spare-parts supply (recurring revenue and higher margin over time).
• Custom/industrial projects: bespoke detector arrays and inspection systems for non-clinical industrial customers.

• Hardware accounts for the bulk of top-line revenue (~65-70%), with software, licensing and services contributing the remainder (~30-35%) and trending up as SaaS/AI offerings grow.
• Initial hardware sales are lower-margin than recurring service/software contracts, so increases in installed base and service attach rates improve overall EBIT margins over time.
• Export sales-sold in about 80 countries-diversify revenue and reduce single-market dependence; international business typically involves distributor margins but higher ASPs for turnkey systems.

• R&D-led product introductions: annual new product launches in detectors and AI-enabled imaging improve competitiveness and enable price premia.
• Strategic partnerships: collaborations with OEM partners, local distributors and hospital networks accelerate adoption and provide integration into clinical workflows.
• After-sales ecosystem: service agreements and remote/ cloud diagnostics raise lifetime customer value and normalize revenue via recurring fees.
• Segment diversification: serving veterinary, dental, security and industrial customers cushions cyclical demand swings in hospital capital spending.

• Inventory and component sourcing: margins can be affected by semiconductor and panel supply cycles; inventory management is key to preserving cash conversion.
• Channel mix: direct sales yield higher gross margins but higher SG&A; distributor models scale faster internationally but reduce per-unit margin.
• R&D investment: sustained R&D (≈8-9% of revenue) fuels long-term product differentiation but temporarily reduces free cash flow.
• Service attach and installed base growth: higher installed base increases recurring revenue share and stabilizes cash flows versus capital equipment sales volatility.

• OEM integrations with imaging system vendors to supply detectors as component business.
• Distribution agreements across APAC, EMEA and the Americas enabling presence in ~80 countries.
• Collaborations with academic and clinical research centers to validate AI modules and speed regulatory approvals.

iRay Technology Company Limited (688301.SS): How It Makes Money

• Core product sales: flat-panel X-ray detectors, DR/CT detector modules, digital imaging systems sold to OEMs, hospitals, and integrators.
• System solutions: turnkey security inspection systems and industrial inspection equipment.
• After-sales & services: maintenance contracts, spare parts, calibration and software upgrades.
• Licensing & OEM partnerships: technology licensing and module supply agreements with global equipment manufacturers.
• New verticals: expansion into scientific instruments, security checks, and non-destructive testing (NDT).

• Stable public valuation with a market cap of 21.22 billion RMB and a 100.50 RMB share price (12 Dec 2025), indicating investor confidence in core technologies.
• Broad international reach - exports to ~80 countries - provides diversified revenue streams and resilience against regional demand shocks.
• Investment in R&D and downstream product expansion (security checks, scientific instruments) supports medium-term revenue growth and margin improvement.
• Adoption of ESG and green development principles enhances appeal to institutional and sustainability-focused investors.
• Corporate rebranding to iRay Group (Feb 2025) signals strategic professionalization and intention to scale globally.